Kranial Radyonekroz ve Tedavisi
Özet
Kranial radyasyon nekrozu (RN), stereotaktik radyocerrahi (SRS) ve tüm beyin radyoterapisi gibi intrakranial tümör tedavilerinin ardından aylarca veya yıllarca sürebilen ciddi bir lokal geç doku reaksiyonudur. Uzun vadeli sağkalım oranlarının artmasıyla önemi büyüyen bu patoloji, vasküler endotel hasarı, kan-beyin bariyeri bozulması ve inflamatuar sitokinlerin salınımı gibi çok faktörlü mekanizmalarla tetiklenir. Akut, subakut ve kronik olmak üzere üç alt türde gelişen RN; doz-hacim etkileşimi, önceki radyasyon maruziyeti ve eş zamanlı kemoterapi kullanımı gibi faktörlerden doğrudan etkilenir. Tanı aşamasında, lezyonların tümör nüksünden ayırt edilmesi zorlu bir süreç olup, FDG PET, T1 SPECT, perfüzyon MR ve manyetik rezonans spektroskopi (MRS) gibi ileri görüntüleme yöntemlerinin entegrasyonunu gerektirir. Tedavi yaklaşımı ise semptomların varlığına göre şekillenir; küçük veya asemptomatik vakalarda yakın klinik takip yeterli olurken, semptomatik hastalarda ilk basamak olarak ödemi azaltan kortikosteroidler tercih edilir. Steroide dirençli olgularda VEGF hedefli bevacizumab kullanımı, hiperbarik oksijen tedavisi ya da lazer interstisyel termal tedavi (LITT) gibi yenilikçi modaliteler öne çıkmaktadır; kitle etkisinin giderilmesi gereken dirençli vakalarda ise cerrahi rezeksiyona başvurulmaktadır.
Cranial radiation necrosis (RN) is a severe, localized late tissue reaction that emerges months or years following intracranial tumor treatments such as stereotactic radiosurgery (SRS) and whole-brain radiation therapy. Increasingly significant due to prolonged patient survival rates, its complex pathophysiology is driven by initial vascular endothelial damage, blood-brain barrier disruption, and inflammatory cytokine cascades. Developing through acute, subacute, or chronic phases, RN risk is strictly modulated by predictive parameters including dose-volume interactions, previous radiation exposures, and concurrent chemotherapy usage. Diagnostic differentiation between necrosis and tumor recurrence remains highly challenging, necessitating advanced imaging modalities such as FDG PET, T1 SPECT, perfusion MRI, and magnetic resonance spectroscopy (MRS). Therapeutic management is strictly tailored based on clinical symptoms; small, asymptomatic lesions are managed through vigilant observation, whereas symptomatic presentations require immediate first-line oral corticosteroids to mitigate localized edema. For steroid-refractory instances, the anti-VEGF agent bevacizumab, hyperbaric oxygen therapy, or laser interstitial thermal therapy (LITT) offer viable treatment pathways, while surgical resection is reserved for intractable, symptomatic mass effects.
Referanslar
Chao ST, Ahluwalia MS, Barnett GH et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. International journal of radiation oncology, biology, physics. 2013; 87(3): 449–457.
Fischer AW, Holfelder H. Lokales Amyloid im Gehirn. Dtsch Zeitschrift Für Chir. 1930; 227: 475–83.
Loganadane G, Dhermain F, Louvel G, et al. Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients. Frontiers in oncology. 2018; 8: 336.
Ali FS, Arevalo O, Zorofchian S, et al. Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities. Current oncology reports. 2019; 21(8): 66.
Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. International journal of radiation oncology, biology, physics. 2006; 65(2): 499–508.
Rahmathulla G, Marko NF, Weil RJ. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2013; 20(4): 485–502.
Chin LS, Ma L, DiBiase S. Radiation necrosis following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow up. Journal of neurosurgery. 2001; 94(6): 899–904
Mehta S, Shah A, Jung H. Diagnosis and treatment options for sequelae following radiation treatment of brain tumors. Clinical neurology and neurosurgery. 2017; 163: 1–8.
Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiation oncology (London, England). 2011; 6 :48.
Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. International journal of radiation oncology, biology, physics. 1991; 21(3): 601–606.
Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20(9): 2267–2276.
Langleben DD, Segall, G. M. PET in differentiation of recurrent brain tumor from radiation injury. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2000; 41(11): 1861–1867.
Kohutek ZA, Yamada Y, Chan TA, et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. Journal of neuro-oncology. 2015; 125(1): 149–156.
Sneed PK, Mendez J, Vemer-van den Hoek JG, et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. Journal of neurosurgery. 2015; 123(2): 373–386.
Le Rhun E, Dhermain F, Vogin G, et al. Radionecrosis after stereotactic radiotherapy for brain metastases. Expert review of neurotherapeutics. 2016; 16(8): 903–914.
Colaco RJ, Martin P, Kluger HM. et al. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? Journal of neurosurgery. 2016; 125(1): 17–23
Fang P, Jiang W, Allen P, et al. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. Journal of neuro-oncology. 2017; 133(3): 595–602.
Kim JM, Miller JA, Kotecha R, et al. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. Journal of neuro-oncology. 2017; 133(2): 357–368.
Cuccurullo V, Di Stasio GD, Cascini GL, et al. The Molecular Effects of Ionizing Radiations on Brain Cells: Radiation Necrosis vs. Tumor Recurrence. Diagnostics. 2019; 9(4): 127.
Balentova S, & Adamkov M. Molecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A Review. International journal of molecular sciences. 2015; 16(11): 27796–27815.
Abdulla S, Saada J, Johnson G, et al. Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. Clinical radiology. 2015; 70(11): 1299–1312.
Fajardo LF, Berthrong M. Vascular lesions following radiation. Pathology annual. 1988; 23 Pt 1: 297–330.
Kudo S, Suzuki Y, Noda SE, et al. Comparison of the radiosensitivities of neurons and glial cells derived from the same rat brain. Experimental and therapeutic medicine. 2014; 8(3):754–758.
Nordal RA, Nagy A, Pintilie M, et al. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(10): 3342–3353.
Lyubimova N, Hopewell, J. W. Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation-induced CNS injury. The British journal of radiology. 2004; 77(918): 488–492.
Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Molecular interventions. 2004; 4(5): 273–284.
Munier S, Ginalis EE, Patel NV, et al. Radiation Necrosis in Intracranial Lesions. Cureus. 2020; 12(4): e7603.
Walle T, Martinez Monge R, Cerwenka A, et al. Radiation effects on antitumor immune responses: current perspectives and challenges. Therapeutic advances in medical oncology. 2018; 10: 1758834017742575.
Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). International journal of radiation oncology, biology, physics. 1996; 34(3): 647–654.
Blonigen BJ, Steinmetz RD, Levin L, et al. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. International journal of radiation oncology, biology, physics. 2010; 77(4): 996–1001.
Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurgery Study Group. International journal of radiation oncology, biology, physics. 2000; 46(5): 1143–1148.
Miller JA, Bennett EE, Xiao R, et al. Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. International journal of radiation oncology, biology, physics. 2016; 96(5): 1060–1069.
Raaphorst GP, Malone S, Alsbeih G, et al. Skin fibroblasts in vitro radiosensitivity can predict for late complications following AVM radiosurgery. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2002; 64(2): 153–156.
Dequesada IM, Quisling RG, Yachnis A, et al. Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study. Neurosurgery. 2008; 63(5): 898–904.
Kano H, Kondziolka D, Lobato-Polo J, et al. T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery. 2010; 66(3): 486–492.
Mitsuya K, Nakasu Y, Horiguchi S, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. Journal of neuro-oncology. 2010; 99(1): 81–88.
Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR. American journal of neuroradiology. 1998; 19(3): 407–413.
Thompson TP, Lunsford LD, Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotactic and functional neurosurgery. 1999; 73(1-4): 9–14.
Serizawa T, Saeki N, Higuchi Y, et al. Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors. Journal of neurosurgery. 2005; 102 Suppl: 266–271.
Degaonkar MN, Pomper MG, Barker PB. Quantitative proton magnetic resonance spectroscopic imaging: regional variations in the corpus callosum and cortical gray matter. Journal of magnetic resonance imaging : JMRI. 2005; 22(2): 175–179.
Wang YX, King AD, Zhou H, et al. Evolution of radiation-induced brain injury: MR imaging-based study. Radiology. 2010; 254(1): 210–218.
Patel TR, McHugh BJ, Bi WL, et al. A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR. American journal of neuroradiology. 2011; 32(10): 1885–1892.
Kotsarini C, Griffiths PD, Wilkinson ID, et al. A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery. 2010; 67(6): 1799–1815.
Tye K, Engelhard HH, Slavin KV, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. Journal of neuro-oncology. 2014; 117(2): 321–327.
Williamson R, Kondziolka D, Kanaan H, et al. Adverse radiation effects after radiosurgery may benefit from oral vitamin E and pentoxifylline therapy: a pilot study. Stereotactic and functional neurosurgery. 2008; 86(6): 359–366.
Kohshi K, Imada H, Nomoto S, et al. Successful treatment of radiation-induced brain necrosis by hyperbaric oxygen therapy. Journal of the neurological sciences. 2003; 209(1-2): 115–117.
Ahluwalia M, Barnett GH, Deng D, et al. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. Journal of neurosurgery. 2018; 130(3): 804–811.
